Amyotrophic lateral sclerosis.

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss, leading to paralysis and eventual death.
• Multiple molecular pathways, including SOD1 mutations, oxidative stress, excitotoxicity, and protein aggregation, are implicated in ALS pathogenesis.
• The role of insulin signaling and the potential involvement of multiple mechanisms in sporadic ALS cases warrant further investigation.

Purpose of the Study:

• To review suggested molecular pathways involved in motor neuron degeneration in ALS.
• To evaluate the efficacy of existing and potential therapeutic agents for ALS.
• To explore novel treatment modalities and the importance of understanding endogenous factors in neurodegeneration.

Main Methods:

• Review of scientific literature on ALS molecular pathways and therapeutic strategies.
• Analysis of clinical trial data for approved and investigational ALS drugs.
• Discussion of emerging treatment approaches, including peptides, proteins, and stem cells.

Main Results:

• Riluzole and Edaravone are FDA-approved treatments for ALS, while Talampanel and Tamoxifen show significant benefit.
• Insulin Growth Factor-1 (IGF1) modulation yielded inconclusive results as a potential ALS treatment.
• Many compounds effective in mouse models have failed in human clinical trials, highlighting the complexity of ALS.

Conclusions:

• Developing effective ALS treatments may require drugs targeting multiple molecular pathways, especially for sporadic cases.
• Further research into endogenous factors driving neuron death, protein aggregation, and oxidative stress is essential for improved drug design.
• Novel therapeutic modalities like cell-based therapies offer promising avenues for future ALS treatment.